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ABSTRACT
Objectives: The current work presents a formulation of curcumin-loaded transethosome (CRM-TE) in the form of a gel and its characterization.
Methods: Thirteen formulations were prepared by varying the concentration of Phospholipon 90G as lipid, ethanol, and ratio of lipid: Span using Box-
Behnken Design. The optimized formulation was characterized by vesicle size, entrapment efficiency, drug retention, drug permeation through skin, 
and morphology. Parameters of CRM-TE were compared to other vesicular systems that include liposomes, ethosomes, and transfersomes. Optimized 
CRM-TE was incorporated into gels, and comparative evaluation was performed. CRM-TE gel was kept at 5±3°C, 25±3°C, and 40±3°C for 180 days, 
further evaluated for entrapment efficacy and vesicle size.
Results: CRM-TE showed 286.4 nm vesicle size, 61.2% entrapment efficiency, 19.8% drug retention, and 71.3% drug permeation at 24 h in the skin. It 
was found superior in terms of all the parameters as compared to other vesicular formulations. CRM-TE gel also exhibited best characteristics in terms 
of entrapment efficiency, drug retention, and drug permeation. CRM-TE gel exhibited better stability at 5±3°C in terms of vesicle size and entrapment 
efficiency as compared to other storage conditions.
Conclusion: CRM-TE gel could offer efficient delivery of curcumin through topical route.
Keywords: Curcumin, Transethosome, Curcumin-loaded transethosome gel, Box-Behnken Design, Stability studies.
INTRODUCTION
Curcumin is obtained from rhizomes of Curcuma longa that belongs to 
Zingiberaceae family [1]. It is one of the most widely used drugs for the 
treatment of arthritis, cancer, various inflammatory, neurodegenerative, 
dermal, metabolic disorders, and viral diseases [2]. It exhibits its 
anti-inflammatory effect by the inhibition of cyclooxygenase-II and 
lipoxygenase, suppressing the activation of nuclear factor-κB. Being 
such a promising therapy in the treatment of many disorders, its use 
is limited due to its low aqueous solubility (0.0004 mg/ml at pH 7.3) 
leading to its low oral bioavailability.
Only the traces of curcumin observed after oral administration due 
to its poor absorption (up to 8 g/day) [3]. Since the patients suffering 
from diseases where long-term therapy is required (e.g. arthritis) have 
to take the drug on daily basis throughout their lives, drug may get 
deposited in the tissues, leading to further complications. Hence, in the 
present work, an attempt was made to develop a topical drug delivery 
system to increase the bioavailability of the drug. Bypassing of the first 
pass metabolism and local action could be achieved by the proposed 
delivery system. Very small dose of orally administered formulations 
about 25–45% reaches the blood circulation due to the first pass effect. 
To overcome these limitations, the concept of gel formulations comes 
into existence for topical applications [4].
Despite these expected advantages, conventional topical systems 
reported hitherto, show many limitations in terms of deeper penetration 
of the skin. This problem can be overcome by the use of vesicular drug 
delivery systems such as liposomes (L), niosomes, transfersomes (T), 
and ethosomes (E) [5]. The problem of the low flexibility of L could 
be overcome by the use of E and T. T are composed of lipids and edge 
activators while E are composed of lipid and ethanol, leading to high 
permeation of drug [6]. Transethosomes (TE) are a new generation of 
vesicles which interplay the role of E as well as T [5]. These contain 
lipid, ethanol as well as edge activator such as span 80, span 60, and 
tween 80 and therefore, synergize the properties of both E and T [6].
In the present study, formulation of TE has been attempted, and the 
developed carrier system has been successfully applied to formulate 
gel for the topical delivery of curcumin. Optimization of formulation 
variables that could affect the formulation properties of TE has also 
been carried out using Box-Behnken design (BBD).
MATERIALS AND METHODS
Materials
Curcumin was procured from Sanjay Biologicals Pvt. Ltd., Amritsar, 
Punjab, India. Phospholipon 90 and 70 G (PL 90 G and 70 G), egg 
lecithin was gifted by Lipoid, Germany. Sephadex G-50 (medium) 
was purchased from M/s Sigma-Aldrich, St. Louis, USA. Span 20, 60, 
80, tween 20, 40, 80, and ethanol were procured from Loba Chemie 
Pvt. Ltd, Mumbai, India. All the other chemicals used for formulation 
development were of analytical grade. Double distilled water was used 
throughout the study.
High-performance liquid chromatography (HPLC) method for 
curcumin
Estimation of curcumin was carried out using reverse phase HPLC 
(LC-20 AD; Shimadzu, Japan). The stationary phase used was C-18 
reverse phase column (Nucleodur C18). The length of the column was 
250 mm, width 4.6 mm and internal diameter was 5 µm. The mixture 
of 60% v/v acetonitrile and 40% v/v acetate buffer (5%) was used as 
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a mobile phase at a flow rate of 1 mL/min. Photodiode array detector 
(SPDM20A; Shimadzu, Japan) with a 20 µL loop (Rheodyne) was used 
to quantify the drug at 420 nm. LC Solution software was used as data 
station. The prepared calibration curve found linear in the range of 
2–10 µg/mL with r2 value of 0.9939 and retention time of 6.9 min.
Preliminary screening studies
Preliminary screening studies were carried out to identify suitable 
levels for the formulation variables influencing physicochemical 
properties of vesicles. Different lipids, for example, Oya phospholipid 
(PL 90 G, PL 70 G), egg phospholipid (egg lecithin), and edge activators 
(Span 20, 60, and 80, tween 20, 40, and 80) were used. During the 
preliminary studies, results revealed that among lipids used, PL 90 G 
and among the edge activators, span 80 showed the best results. Hence, 
these two were selected as independent variables. Using various ratios 
of these two along with ethanol, further formulations were designed. 
A total of 20 formulations were prepared using 10–40% ethanol and 
1–5% lipid and lipid and span 80 in the ratio of 85:15 (Table 1). The 
prepared formulations were evaluated for entrapment efficiency, 
percentage transmittance, and optical microscopy as the responses in 
preliminary screening studies.
Formulation of TE and other vesicles
For the preparation of vesicles, three different methods (a) ethanol 
injection method, (b) thin film hydration method, and (c) rapid ethanol 
injection method were used. Among them, ethanol injection method 
was found to give best results. 20 different formulations were prepared 
using formula compositions that are mentioned in Table 1. Combination 
of PL 90 G (phospholipid) and Span 80 (edge activator) was used for the 
formulation of vesicles. Lipid, edge activator, and drug (curcumin) were 
weighed accurately and dissolved in ethanol. Phosphate buffer (pH 7.4) 
was maintained at a temperature of 50°C in another vessel. Ethanolic 
solution of PL 90 G, Span 80, and drug was injected into aqueous 
solution dropwise at the rate of 1 ml/min with constant stirring [6].
Design of experiment
Initial screening trials were conducted to evaluate the formulation 
parameters that may influence the properties of vesicles. Factors such 
as percentage of edge activator, lipid, and ethanol were taken as critical 
parameters of the formulation. Based on the number of factors and 
their levels, BBD was applied to evaluate the effect of formulation and 
processing parameters affecting physical properties of TE. Percentage 
of SPL 90, ethanol, and SPL 90: Span 80 ratio was taken as critical 
parameters that may influence the entrapment efficacy, vesicle size, and 
skin permeation of the vesicles. These three parameters were operated 
at three levels (+1, 0, and −1). The concentration of the drug, type of 
phospholipid and type of edge activator were kept same for all the 
experiments. Design-Expert 9.0.3 software (Stat-Ease, USA) was used 
to conduct the study. A total of 13 formulations were designed by the 
software with 2 centric points. Experiments were run in random order 
to increase the predictability of model. The independent factors and 
their design level used in the study is shown in Table 2.
Characterization of prepared formulation
Drug entrapment efficiency
Entrapment efficiency of the prepared formulations was studied by 
mini column centrifugation method according to the method reported 
by Garg et al. (2016), using the following equation [6].
= ×
Amount of entrapped drugPercentage entrapment efficiency 100
Total amount of drug  
 (1)
Vesicle size analysis
Vesicle size and size distribution study was done using Beckman Coulter 
(Delsa nano®) using dynamic light spectroscopy. Study was conducted 
in triplicate and mean data were recorded.
Ex vivo skin permeation study
Fresh abdominal skin of goat was used for skin permeation studies. Skin 
was obtained from local slaughterhouse. The tissue was then washed 
with distilled water to remove the mucous and other adhered matrices. 
Tissues of about 0.2 mm thickness and 3 cm length were mounted 
on Franz diffusion cell having surface area of 1.79 cm2 and volume of 
25 mL. The tissue was stabilized using mixture of methanol and 0.2M 
phosphate buffer saline (pH 7.4) in the ratio of 1:9 as medium, in both, 
donor and receptor compartments with magnetic stirring for 30 min. At 
the end of 30 min, the existing buffers in both the compartments were 
replaced with fresh medium. The receptor compartment was stirred at 
100 rpm. Formulation (1 ml) was kept in donor compartment over the 
goat skin which acted as diffusion barrier. Study was conducted for 24 
h. Samples were withdrawn at fixed intervals and replaced with same 
amount of fresh media to maintain sink conditions. Sample analysis 
was carried out using HPLC. Each study was carried out in triplicate 





Lipid (%)  
(mg for 10 ml)
Span 80  













F1 85:15 1 (100 mg) 17.6 10 9 1 66.90±0.01 78.9±0.01
F2 85:15 1 (100 mg) 17.6 20 8 1 24.40±0.01 83.6±0.01
F3 85:15 1 (100 mg) 17.6 30 7 2 45.10±0.01 83.5±0.01
F4 85:15 1 (100 mg) 17.6 40 6 2 57.40±0.01 63.8±0.01
F5 85:15 2 (200 mg) 35.2 10 9 3 59.90±0.01 82.4±0.02
F6 85:15 2 (200 mg) 35.2 20 8 1 61.60±0.01 56.2±0.01
F7 85:15 2 (200 mg) 35.2 30 7 1 83.30±0.01 64.1±0.01
F8 85:15 2 (200 mg) 35.2 40 6 2 88.60±0.02 71.7±0.02
F9 85:15 3 (300 mg) 52.9 10 9 2 31.10±0.02 13.7±0.01
F10 85:15 3 (300 mg) 52.9 20 8 2 51.90±0.01 78.0±0.01
F11 85:15 3 (300 mg) 52.9 30 7 2 73.60±0.01 26.3±0.01
F12 85:15 3 (300 mg) 52.9 40 6 3 24.40±0.01 56.8±0.02
F13 85:15 4 (400mg) 70.55 10 9 3 28.71±0.01 39.0±0.01
F14 85:15 4 (400 mg) 70.55 20 8 2 21.13±0.01 42.0±0.01
F15 85:15 4 (400 mg) 70.55 30 7 2 52.00±0.01 8.3±0.01
F16 85:15 4 (400 mg) 70.55 40 6 1 55.22±0.01 31.4±0.01
F17 85:15 5 (500 mg) 88.2 10 9 2 15.81±0.01 23.1±0.01
F18 85:15 5 (500 mg) 88.2 20 8 2 39.60±0.01 21.7±0.02
F19 85:15 5 (500 mg) 88.2 30 7 1 87.00±0.01 13.9±0.03
F20 85:15 5 (500 mg) 88.2 40 6 1 64.50±0.02 31.0±0.004
SD: Standard deviation
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and mean was recorded. The permeation profile was constructed by 
plotting percentage of drug permeated versus time (h).
Skin retention study
Skin was washed with 0.2 M phosphate buffered saline (7.4 pH) 
3–4 times to remove the adhered formulation. To confirm the complete 
removal of any adhering drug, the washings were subjected to HPLC. 
The absence of drug peak indicated that the skin was free from any 
adhered drug. Cleaned skin was cut into small pieces and kept in 
mixture of methanol and 0.2 M phosphate buffer saline (pH 7.4) in the 
ratio of 1:9 for 24 h to extract out the drug deposited inside the skin. 
After 24 h, the medium was sonicated and centrifuged. Supernatant was 
collected and analyzed using HPLC for quantitation of drug. Each study 
was condcuted in triplicate and mean data were recorded.
Morphological study of optimized batch of TE (OTE)
The optimized formulation was evaluated for its morphology by 
transmission electron microscopy (TEM). A drop of the diluted sample 
was placed on a microscopic copper-coated grid for drying. After 
complete drying, a drop of a 1% phosphotungstic acid aqueous solution 
was added for negative staining. Excess solution was wiped off after 45 
s and sample was analyzed under microscope at different magnification 
values [7].
Stability study of OTE
Optimized formulation was kept at 5±3°C, 25±3°oC, and 40±3°C for 
180 days, further evaluated for entrapment efficacy and vesicle size.
Preparation of other vesicles
To compare the potential of developed TE in terms of physical properties, 
other vesicles such as L, transfersome (T), and ethosome (E) were also 
prepared. The composition of these vesicles is presented in Table 3. 
Ethosomes were prepared by the same method as that TE, whereas 
L and transfersome were prepared by thin film hydration method. 
PL 90 G, Span 80, and drug were weighed accurately and dissolved 
in chloroform/methanol (2:1 v/v). This solution was evaporated on 
a rotary evaporator at 50°C under reduced pressure. The thin film 
obtained was hydrated with pH 7.4 phosphate buffer. The suspension 
was kept overnight for complete hydration of the vesicles [6].
Preparation of vesicular gel formulation
All the prepared vesicles were incorporated into Carbopol 934® gel 
1% w/w. These were termed as optimized TE based gel (OTEG), 
transfersome based gel (TG), ethosome based gel (EG), and liposome-
based gel (LG), respectively. Gel was prepared by incorporating 
vesicular dispersion equivalent to 0.5% w/w of drug to 10% w/w of 
Carbopol 934® gel. The final composition of the gel thus was 1% w/w 
of Carbopol gel. Triethanolamine was added to the gel to impart the 
desired consistency and pH (5.1).
Characterization of prepared gel
Appearance and pH
The prepared gel was evaluated visually for pH, clarity, color and 
presence of any particles. Two grams of gel were stirred in distilled 
water and volume was made up to 50 mL. pH was measured using 
digital pH meter.
Measurement of viscosity
Viscosity of the prepared formulation was determined using Brookfield 
viscometer at different shear rates and torque values. Spindle No. 64 
was used to measure the viscosity. Measurement was done over the 
range of 2–100/s.
Ex vivo skin permeation study of gel formulations
Drug release from TE based gel was compared with transfersome, 
ethosome, and liposome-based gel using results of skin permeation 
study that was carried out for 24 h. Drug permeation study of gel was 
performed in a similar way as described previously for vesicles. Gel (1 g) 
was used in donor compartment. Various release mechanisms such 
as zero-order, first-order, Higuchi, and Hixson-Crowell were fitted to 
optimized and other gel formulations to find out the release mechanism.
Skin retention study of gel formulations
Skin retention of OTEG was compared with transfersome, ethosome, 
and liposome-based gel. The study was conducted in similar manner as 
described for vesicle-based formulation. Each study was carried out in 
triplicate and mean data were recorded.
Table 2: Box-Behnken Design deciphering design levels of independent variables and their responses
Formulation 
code
Lipid (%) (A) Lipid: Span 
80 (B)









A1 4 (+1) 11.5 30 (+1) 740.00±0.01 52.31±0.01 73.70±0.01
A2 1 (−1) 4 (−1) 20 (0) 710.00±0.01 41.01±0.01 27.20±0.01
A3 2.5 (0) 19 (+1) 10 (−1) 493.70±0.02 49.67±0.01 37.70±0.02
A4 2.5 (0) 19 (+1) 30 (+1) 442.30±0.01 64.30±0.02 52.90±0.01
A5 4 (+1) 11.5 (0) 10 (−1) 470.80±0.02 41.70±0.02 70.80±0.02
A6 2.5 (0) 11.5 (0) 20 (0) 734.40±0.02 65.50±0.02 22.30±0.01
A7 1 (−1) 11.5 (0) 10 (−1) 967.30±0.02 43.00±0.02 49.90±0.02
A8 2.5 (0) 4 (−1) 30 (+1) 1175.00±0.03 75.80±0.02 80.20±0.02
A9 1 (−1) 11.5 (0) 30 (+1) 303.60±0.01 49.96±0.01 66.70±0.02
A10 2.5 (0) 4 (−1) 10 (−1) 654.40±0.01 57.87±0.01 44.70±0.02
A11 1 (−1) 19 (+1) 20 (0) 874.40±0.02 57.42±0.01 11.80±0.01
A12 4 (+1) 19 (+1) 20 (0) 413.00±0.01 49.70±0.02 82.30±0.02
A13 4 (+1) 4 (−1) 20 (0) 844.50±0.02 46.33±0.02 84.00±0.01
*n: No of replicates of study conducted. SD: Standard deviation
Table 3: Composition of vesicles
Formulation code Phospholipon 90 G (%w/v) Lipid: Span 80 Ethanol (%) Chloroform: Methanol
OTE 3.49 19.00 30 -
T 3.49 19.00 - 2:1
E 3.49 19.00 30 -
L 3.49 19.00 - 2:1
OTE: Optimized batch of transethosomes, T: Transfersome, E: Ethosome, L: Liposomes
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Statistical analysis
All the results are expressed as mean±standard deviation. Analysis 
of variance (ANOVA) was used as statistical tool to find possible 
correlations using GraphPad Prism version 7 (GraphPad Software Inc., 
CA, USA). The results were found significant where p<0.05. All the 
studies related to design and optimization of formulation was carried 
out using Design-Expert 9.0.3 software.
RESULTS AND DISCUSSION
Response surface analysis using BBD and optimization of 
formulation
For the preparation of vesicles, three different methods (a) ethanol 
injection method, (b) thin film hydration method, and (c) rapid ethanol 
injection method were used. The amount of lipid and ethanol was kept 
constant at 3% w/v and 30% v/v, respectively. The ratio of lipid to span 
80 was varied in the range of 75:25–95:5. The study revealed different 
types of responses for different methods used. In case of ethanol 
injection method (P11), the results of optical microscopy revealed the 
presence of high amount of debris along with high agglomeration rate. 
This method was, therefore, not used for further studies. Film hydration 
method (P6-10) produced spherical and multilamellar vesicles. These 
were not considered optimum due to the desirability of unilamellar 
vesicles (ULVs) because of the requirement of transdermal delivery [8]. 
Moreover, drug leaching has been reported to be high in case of 
multilamellar vesicles (MLVs) [9]. Formation of ULVs was observed 
when vesicles were prepared using ethanol injection method (P1-5). 
Hence, ethanol injection method was used for further preparations.
It is important to note that on variation in the ratio of lipid 
(Phospholipon 90) to span 80, no significant differences in terms 
of vesicle morphology and percent transmittance were observed in 
any case except formulation P3. In case of P3, there was the absence 
of agglomeration and percentage transmittance was comparatively 
higher. High percentage transmittance value is an indication that vesicle 
size would be comparatively smaller [10].
Hence, to select critical formulation variables along with their ratios, 
20 different formulations (F1–F20) were further explored by varying 
lipid (1–5% w/v) and ethanol concentration (10–40%v/v). It can be 
noted that lipid to span 80 ratios was kept 85:15 since it has provided 
good results. The results of responses are shown in Table 1. It was 
observed from optical microscopy that in formulations F1, 2, 6, 7, 16, 
19, and 20, agglomeration rate was very less and spherical ULVs were 
formed (results not shown). However, in formulation F5, 12, and 13 
agglomeration rates were found to be very high. In formulations F5, 
6, 13, 15, 16, and 17, vesicles were spherical in shape but with a high 
amount of debris. Entrapment efficiency for formulations was found 
in a range of 12.3–88.6%. It was observed that F8 formulation showed 
maximum entrapment efficiency, i.e., 88.6%. From transmittance data, it 
was observed that F2 formulation showed the highest value, i.e., 83.6%. 
Significant changes were observed in entrapment efficiency as well as 
percentage transmittance when lipid concentration was varied from 1 
to 5% and ethanol concentration from 10 to 40%. Thus, considering 
these responses, lipid concentration was varied between 1 and 4%, 
ethanol concentration between 10% and 30% and the ratio of lipid 
to span 80 was varied in between 4 and 20 for further experimental 
design to optimize the formulation.
A total of 13 experiments using BBD were designed to study the effect of 
ethanol, PL 90, and Span 80 on vesicle size (y1), entrapment efficiency 
(y2), and skin permeation of drug at 24 h (Q24) (y3). The responses are 
illustrated in Table 2.
The data revealed responses y1, y2, and y3 in the range of 303.6 to 
1175 nm, 41.01 to 75.8%, and 11.86 to 84.01%, respectively. The 
significance of model was confirmed through the data obtained by 
carrying out ANOVA as the model Prob was greater than F and p<0.05. 
p value for vesicle size (y1), entrapment efficiency (y2), and skin 
permeation of drug after 24 h (y3) were found to be 0.0108, 0.0004, 
0.0200 and 0.0014, respectively. The model F values for response y1, 
y2, and y3 were 20.26, 38.26, 61.22, and 48.96, respectively, which 
implied that model was significant. The multiple regression terms (R2) 
were also analyzed. The predicted R2 values for response y1, y2, y3, and 
y4 were found to be 0.9906, 0.8310, 0.8188, and 0.9691, respectively. 
Adjusted R2 values for response y1, y2, y3, and y4 were found to be 
0.9918, 0.9622, 0.9693, and 0.9752, respectively. The predicted R2 
value was found to be in closer agreement with adjusted R2 value as 
the difference between adjusted R2 and predicted R2 values is <2. This 
indicated that the model has predicted the responses very well [11]. 
It is important to note that adequate precision measures the signal to 
noise ratio and a ratio >4 is desirable [12]. For responses y1, y3, y3, 
and y4, the ratio was 88.857, 24.267, 27.211, and 40.912, respectively. 
Hence, this model could be used to navigate the design space. The final 
mathematical model in terms of coded factors as described by the 
Design Expert software is shown below in Eqs. (2-4) for responses y1, 
y2, and y3, respectively.
y1 [Vesicle size (nm)]=+691.82–48.37×A–145.06×B+9.34×C–
148.98×AB+233.23×AC–143×BC (2)
y2 [Entrapment efficiency (%)]=+65.50–0.17×A+1.29691×B+6.27×C–
3.26×AB+0.91×AC–0.83×BC–16.03×A2–0.86×B2–2.73×C2 (3)
y3 [Skin permeation of drug at 24 h (%)]=+22.30+13.60×A+ 
13.52×B+10.11×C+15.06×AB+3.49×AC+2.43×BC+27.37×A2+13.33× 
B2+15.63×C2 (4)
In the polynomial equation, a positive sign represents a synergistic 
effect, while a negative sign indicates an antagonistic effect. In case of 
y1, the data revealed that with an increase in PL 90 G concentration 
(A) and ratio of PL 90 G to Span 80 (B), the vesicle size got decreased, 
whereas, with an increase in ethanol concentration, vesicle size got 
increased. This reveals that higher PL 90 G concentration and PL 90 
G to span 80 ratios as well as the lower concentration of ethanol are 
desirable to control vesicle size in the lower range. Moreover, the 
combined effect of Factors A and B and B and C revealed a decrease in 
vesicle size. On the contrary, the combinative effect of A and C causes an 
increase in the vesicle size. As an outcome, it can be understood that the 
concentration of all the factors should be neither too high nor very low 
to get optimum vesicle size.
In case of entrapment efficiency (y2), it was observed that y2 got 
decreased with increased concentration of A, however, at a higher 
level of B and C, entrapment efficiency (y2) of vesicles got increased. 
This revealed that increased level of the ratio of PL 90 G to span 80 
and ethanol was desirable to increase entrapment efficiency of vesicles. 
Ethanol fluidizes the lipid layer of vesicles and thereby increases the 
fluidity as well as the flexibility of vesicles leading to better entrapment 
efficiency [6]. When the combinative effect of factors on y3 was 
observed, the response got decreased with increased concentration of 
Factors AB and BC. On the other hand, it got increased with increase 
in factor AC. This revealed that presence of higher concentration of 
PL 90 G and PL 90 G to span 80 ratios, restricts the penetration of the 
drug in the lipid bilayer, whereas, the presence of ethanol in higher 
concentration nullifies this effect.
In case of skin permeation of drug (y3), the response got significantly 
increased with increase in the concentration of all the three factors. The 
major reason behind this is permeation enhancing capacity of ethanol 
that was further enhanced due to the combined effect of phospholipid 
and span 80 [6].
The obtained regression model helped in generation of 3D response 
surfaces for independent factors (y1 to y3), by keeping one factor constant 
in each case. It was observed from 3D plots that for response y1, vesicle 
size decreased with increase in the concentration of AB (Fig. 1a) and 
BC (Fig. 1b), whereas, it increased with increase in concentration of BC 
(Fig. 1c). The response y2 got decreased with increase in concentration 
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of AB (Fig. 1d) and BC (Fig. 1e). However, it got increased with increase 
in the level of AC (Fig. 1f). The drug permeation was found to increase 
with an increase in all the three variables (Fig. 1g-i).
Employment of graphical optimization method helped in choosing the 
best fit optimum formulation. The data revealed that for an optimum 
formulation with desirable responses, the amount of PL 90 G and PL 
90 G: Span 80 ratio and ethanol percentage should be 3.49% w/v, 
19 (95:5), and 30% v/v, respectively.
Validation and characterization of optimized batch
The optimized batch was prepared using 3.49% w/v of PL 90 G and 95:5 
ratio of PL 90 G: Span 80 and 30% v/v ethanol and characterized for 
entrapment efficiency (%), vesicle size, polydispersity index (PDI), skin 
permeation, and retention of drug. All the parameters were also compared 
among E, T, and L-based formulation. Table 4 shows the entrapment 
efficiency of OTE along with T, E, and L. The data revealed that OTE based 
formulation was found to give the highest value (61.2%) followed by E 
(52.0%). The order of decrease in entrapment efficiency was as follow:
OTE>T>E>L.
Vesicle size and polydispersity index of various types of formulations 
were also compared (Table 4). Vesicle size of OTE was found to be 
least (286.4 nm) as compared to that of the other formulations. PDI of 
OTE was 0.274 indicating homogeneous population and narrow size 
distribution [13]. Vesicle size was found to decrease in following order:
L>T>E>OTE
Skin permeation and retention studies
Data obtained from skin permeation studies revealed that at 24 h, OTE 
showed the highest permeation of the drug (71.3%) whereas, L showed 
the least permeation (40.3%). Fig. 2 shows comparative permeation of 
all the formulations for 24 h. At the end of the 6th h, the permeation of 
drug was found to increase sharply, and this increase was observed to 
continue until 24 h. On the similar pattern, increase in drug permeation 
was also observed in case of E, T, and L. Rate of permeation decreased 
in the order - OTE>T>E>L.
This may be attributed to the fact that liposomes are typically hollow 
spheres surrounded by a lipid doubled layer. Once applied on the skin 
surface, they are retained in the upper layer of the stratum corneum, 
acting as a drug reservoir, whereas, T and E can easily change their 
shape and cross the skin barrier. However, the major limitation of these 
vesicles is their difficulty to load hydrophobic drugs into the bilayer 
without compromising their deformability and elastic properties. TE has 
shown an irregular spherical shape and higher values skin permeation 
compared to other vesicles. Skin retention potential of vesicles was 
also calculated (Fig. 3) and was found highest in case of OTE, i.e. 19.8% 
followed by T, E, and L, i.e. 13.8%, 9.0%, and 7.0%, respectively.
TEM OTE
TEM image of OTE is shown in Fig. 4. The results obtained from drug-
loaded OTE revealed the formation of ULVs having spherical but 
Table 4: Mean (±SD) entrapment efficiency, particle size, and 
PDI of OTE, and other vesicles
Formulation 
code





OTE 61.20±0.01 286.40±0.02 0.27±0.01
T 54.50±0.02 521.20±0.02 0.34±0.01
E 52.00±0.01 391.90±0.01 0.27±0.01
L 43.70±0.02 5737.0±0.02 1.67±0.02
n: No of samples, SD: Standard deviation, OTE: Optimized batch of 
transethosomes, PDI: Polydispersity index
Fig. 1: 3D plots for effect of lipid (phospholipon 90 G), ethanol, lipid to Span 80 ratio on vesicle size (a-c), percentage entrapment 
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irregular shape. The smallest vesicle size observed was 78.12 nm at 
×30000 while in most of the cases, size of vesicles was observed to be 
near 250 nm. It is reported that ULVs have higher potential to permeate 
skin as compared to MLVs.
Stability studies
Table 5 shows the stability data of OTE at 5±3°C, 25±3°C, and 40±3°C 
for 180 days. The data showed that there was a negligible loss of 
entrapped drug at 5±3°C after 180 days of storage. However, at 25±2°C, 
comparatively more loss of drug occurred, and at 40°C, loss was found 
to be highest. This may be explained on the basis of fact that due to loss 
of rigidity of vesicles at high temperature, they assemble to retain the 
drug. Increase in fluidity (loss of rigidity) at higher temperature is due 
to a phase transition. Vesicle size of the formulation also increased at 
high temperature (25±3°C and 40±3°C) which may be due to increase 
in the rate of aggregation of vesicles which were found comparatively 
less at low temperature (5±3°C). It was, therefore, concluded that 
formulation should be kept under refrigerated conditions (5±3°C) to 
avoid any kind of stability problem [14].
Characterization of vesicular topical gel
The prepared gel was transparent having pH 7.4 and viscosity 6145.6 
cps. Data obtained from skin permeation studies (Fig. 2) revealed that 
at 24 h, OTE gel (OTEG) showed the highest permeation of the drug 
(57.5%) whereas, liposomes showed least permeation (16.9%). Skin 
retention potential of vesicles was also calculated, and it was observed 
that OTEG showed highest skin retention potential (21.2%) followed by 
TG, EG, and LG, i.e. 14.9%, 10.3%, and 9.5%, respectively (Fig.3).
Analysis of release mechanism
Drug release data were explored for the type of mechanism involved. 
Release kinetics of OTEG, EG, TG, and LG were studied using different 
kinetic equations (zero-order, first-order, Hixson-Crowell model, and 
Higuchi model). The best fit with a highest correlation coefficient 
(r2) was chosen as the kinetic model. The results revealed that all the 
vesicle-based gel (i.e., OTE, EG, TG, and LG) showed highest correlation 
coefficient using Hixon-Crowell model. This indicated that the vesicular 
gel followed Hixson-Crowell which revealed that the gel formed an 
erodible matrix. Hence, it was concluded that the gel showed anomalous 
diffusion indicating that the formulation showed a controlled release 
pattern which would reduce the frequency of administration and 
increase patient compliance [15].
CONCLUSION
In this present study, TE was prepared containing PL 90 G, Span 80, 
and ethanol. These were evaluated for their drug permeation and 
retention at 24 h, vesicle size, and entrapment efficiency. BBD was used 
to optimize the ratios of PL 90 G, Span 80, and ethanol. Formulation 
with a high percentage of ethanol (30%) and lipid: Span ratio of 95:5 
was found to show optimum characteristics. The developed TE based 
formulation was found to be more effective when compared to other 
vesicular delivery systems (i.e., L, E, and T) in terms of skin permeation 
of drug at 24 h, skin retention, vesicle size, and entrapment efficiency. 
The prepared formulation was found stable at 5±3°C for 180 days. The 
OTE loaded with curcumin was incorporated into gel composed of 
1% w/w Carbopol and evaluated for rheology, permeation of drug, and 
drug retention in the skin. The highest drug permeation, as well as drug 
retention in skin prolonged drug release, was observed with OTEG. The 
Hixson-Crowell model of release kinetics revealed that the gel released 
the drug as an erodible manner. Hence, it can be concluded that the 
developed TE was found superior over other vesicular delivery systems 
and have been successfully applied as a carrier to topical delivery in 
the form of a gel. However, the obtained results of in vitro and ex vivo 
experiments need to be correlated with in vivo studies.
Fig. 2: Mean (±standard deviation) comparative percentage skin 
permeation of curcumin from vesicles and their gel formulation
Fig. 3: Mean (±standard deviation) percentage skin retention 
potential of vesicles and their gel formulation
Fig. 4: Transmission electron microscopy image of optimized 
formulation of optimized batch of transethosomes
Table 5: Entrapment efficiency, vesicles size, and PDI of OTE at 
different temperatures after 180 days under different stability 
conditions






5±3°C 59.20±0.01 358.30±0.01 00.29±0.02
25±3°C 52.60±0.01 421.40±0.01 00.32±0.01
40±3°C 30.10±0.01 564.20±0.01 00.38±0.01
n: Number of samples, SD: Standard deviation, OTE: Optimized batch of 
transethosomes, PDI: Polydispersity index
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